Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points The FDA has accepted the NDA for Laundrostat for the treatment of hypertension, with a PDUFA target action date set for December 22, 2026. Mineralys Therapeutics Inc ( NASDAQ:MLYS ) has completed five positive clinical trials demonstrating clinically meaningful blood pressure reduction and a favorable safety profile. The company has a strong financial position with cash equivalents and investments of $656.6 million, sufficient to fund operations into 2028. There is significant market opportunity with over 20 million people in the U.S. affected by uncontrolled and resistant hypertension. Mineralys Therapeutics Inc ( NASDAQ:MLYS ) is actively engaging in market access planning and payer engagement to ensure a successful launch of Laundrostat. Negative Points The exploratory trial Explore OSA did not demonstrate a clinically meaningful difference on the pri
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mineralys Therapeutics (MLYS) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MLYS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Mineralys Therapeutics (MLYS) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 3/12/26 - Beat
MLYS
Sec Filings
- 3/17/26 - Form 144
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- MLYS's page on the SEC website